Sudoc Catalogue:: - Livre / BookRecent advances in the treatment of multiple myeloma: [proceedings of a European expert meeting] / guest editor H. Grant Prentice. Multiple myeloma MM is among the most common hematologic malignancies. Current milestones of MM therapy include either a triple- or double-drug combination, based on proteasome inhibitors PIs and/or immunomodulatory imide drugs IMiDs plus dexamethasone with or without chemotherapy. Sep 15, 2012 · Abstract. Multiple myeloma represents about 1% of all cancers and 10–20% of all hematologic malignancies. The clonal proliferation of malignant plasma cells in the bone marrow may result both in local growth and in systemic effects due to the overproduction of.
T he treatment of mul ple myeloma has improved significantly over the past 10 to 15 years, more than doubling the overall survival of the disease. 1, 2 In the recent IFM trial, the 4-year survival. Jun 27, 2010 · The past decade has witnessed significant advances in the treatment of multiple myeloma with the introduction of high-dose therapy and stem cell transplantation into routine clinical practice, as well as the approval by the Food and Drug Administration FDA of four therapeutic agents, namely, lenalidomide, thalidomide, bortezomib, and pegylated liposomal doxorubicin, with each demonstrating survival benefit in patients with the disease. Treatment of multiple myeloma, a B-cell cancer, is usually palliative, however, as a result of intensive clinical research there are numerous new treatment options available today.
Until the advents of novel agents, partial response PR or better was the established gold standard to initial therapy of multiple myeloma MM, and treatment goals were focused on relieving. The median number of cycles completed was 8 range 1–8. Thirty‐three patients exhibited control of their disease 94·4%, defined as some form of a response to treatment n = 30 or as stable disease SD, n = 3.The median time to first response was 1 month range 0·7–11·8, and the median time to best response was 3·5 months range 0·8‐11·8.
May 15, 2017 · In recent research history, monoclonal antibody therapies for multiple myeloma have targeted CD48, signaling lymphocytic activation molecule family 7 protein SLAMF, and IL-6. CD48 has been proposed as a target for monoclonal antibody therapies because it is known to specifically be expressed by cells within the hematopoietic lineage . Oct 22, 2015 · Recent advances in the management of AL Amyloidosis. Efstathios Kastritis. Chemotherapy for AL amyloidosis is based on regimens used for the treatment of myeloma, with adaptations in terms of dose and schedule. In the USA, HDM with ASCT is used more extensively than in Europe Wechalekar et al, 2015.
Nov 15, 2012 · Per protocol, patients also received intravenous bortezomib 1·0 mg/m 2 over 3–5 s on days 1, 4, 8, and 11 of each 28‐d treatment cycle, a regimen that the Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma CREST showed to be clinically active CRPR 30% but with a lower incidence of PN. Apr 03, 2014 · 1.1. Myeloma Intraclonal Heterogeneity. Alongside aiding the characterisation of genes and pathways disrupted in myeloma, molecular studies have also revealed that intraclonal heterogeneity is a common feature of the malignancy [5, 6].This heterogeneity adds an extra layer of complexity to myeloma progression as it is apparent that genetic “hits” are not acquired in a linear fashion but. Multiple myeloma is an incurable disease, although patient survival has increased with the availability of novel agents. Both multiple myeloma and its therapies often affect the renal, immune.
Autologous stem cell transplantation ASCT remains a standard of care for multiple myeloma patients who are eligible to receive high-dose therapy, recognizing that the optimal timing and. Erythropoietin Epo is the main growth regulator of red blood cells, and recombinant human erythropoietin rHuEpo is thus used in clinical practice for the treatment of anaemia, primarily in kidney disease and cancer. rHuEpo treatment was found to be associated with prolonged survival of multiple myeloma MM patients. Hence, blocking the IL-6 pathway has also been investigated as a therapeutic treatment for ACD. IL-6 targeting chimeric antibody siltuximab demonstrated decreased hepcidin levels in 97% of multiple myeloma and Castleman disease patients, with 75% of these patients showing haemoglobin increases of > 1.
Sep 03, 2018 · 1 Department of Radiology, The Royal Marsden NHS Foundation Trust, Fulham Rd, London, UK; 2 Division of Radiotherapy and Imaging, The Institute of Cancer Research, 15 Cotswold Road, Sutton, UK. Whole body MRI is recognized as the most sensitive imaging test for the diagnosis of myeloma bone involvement and is recommended by the International Myeloma Working Group for. Introduction. Despite the presence of a variety of chromosomal aberrations, translocations and mutations in essential growth and tumor suppressor genes in multiple myeloma MM cells, oncogenomic studies have identified few differences distinguishing monoclonal gammopathy of unknown significance from MM. 1-3 This finding highlights the essential role of the bone marrow BM microenvironment in.
Lenalidomide and its parental molecule thalidomide have shown therapeutical activity in various malignancies [2–21].The US Food and Drug Administration FDA first approved lenalidomide for the treatment of patients suffering from 5q-myelodysplastic syndrome .However, because of the proven activity of thalidomide in multiple myeloma MM, the clinical activity of lenalidomide has been. Apr 12, 2010 · Kenneth H. Shain, William S. Dalton, The Bone Marrow Microenvironment: Novel Targets to Circumvent Minimal Residual Disease and Drug Resistance in Multiple Myeloma, Advances in Biology and Therapy of Multiple Myeloma, 10.1007/978-1-4614-4666-8, 141-168, 2013.
Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques (v. 44)
Future Perspectives of Gastric Cancer Treatment - From Bench to Bedside (Pathobiology 2011)
Infinite Dimensional Morse Theory and Multiple Solution Problems (Progress in Nonlinear Differential Equations and Their Applications) Kwang-chih Chang
Eosinophils in Allergy and Related Diseases: Workshop, Tokyo, June 2008: Proceedings (International Archives of Allergy and Immunology)
Galois' Dream: Group Theory and Differential Equations
Haematological Malignancy and the Bone Marrow Trephine Biopsy (Pathobiology 07)
Oxidative Stress and Aging (Molecular and Cell Biology Updates)
Prognostic Values of Exercise Testing and Drug Effects on the Exercise ECG: Symposium of the Working Group on Exercise Physiology, Physiopathology and ... Cardiology, Vienna, April 1981: Proceedings
Leukocyte Emigration and Its Sequelae: Satellite Symposium of the 6th International Congress of Immunology, Toronto, Ont., July 1986
Psychiatric Aspects of Chronic Pulmonary Disease (Advances in Psychosomatic Medicine, Vol. 14)
Genitalendometriose (German Edition) M Litschgi
Host Parasite Relationships in Gram-Negative Infections: Dedicated to the Memory of Robert Koch on Occasion of the 100th Anniversary of His Discovery ... Immunology and Allergy, Vol. 33) (v. 33)
Computer-Aided Electromyography (Progress in Clinical Neurophysiology, Vol. 10)
Proteins of the Placenta: Biochemistry, Biology and Clinical Application 5th International Congress on Placental Proteins, Annecy, June 1984
Testing Drugs for the Ageing Brain: Roussel-Uclaf Symposium, Royaumont Abbey, October 1981
Comparative Physiology of Environmental Adaptations European Society for Comparative Physiology and Biochemistry
Resistance Vessels: Physiology, Pharmacology and Hypertensive Pathology: Workshop on Resistance Vessel Abnormalities in Hypertension, Sønderborg, June ... in Applied Microcirculation, Vol. 8)
Morphological and Functional Aspects of Placental Dysfunction (Contributions to Gynecology and Obstetrics, Vol. 9)
Magnetic Resonance in Medicine and Biology: 1st Symposium on Nuclear Magnetic Resonance (NMR), Geneva, October 1983: Proceedings (Progress in Nuclear Medicine, Vol. 8)
International Association of Logopedics and Phoniatrics: 19th Congress, Edinburgh, August 1983: Main Reports
Psychiatric Aspects of Trauma (Advances in Psychosomatic Medicine, Vol. 16)
Medical Society in the City of New York, Vol. 14: Proceedings
Rehabilitation: A Component of Comprehensive Cardiac Care (Bibliotheca Cardiologica, No. 40)
Japanische Kunst 2013. Kunst-Einsteckkalender Fink Emil
Oberhessen (J. Fink Wanderfuhrer) (German Edition) Josef Ziermair
Zur geistigen Einheit von Hermann Brochs Werk: Massenpsychologie, Politologie, Romane (Edition Orpheus) (German Edition) Robert G Weigel
Impressionisten 2013. Kunst-Postkartenkalender Fink Emil
Flanerie, Sammlung, Spiel: Die Erinnerung des 19. Jahrhunderts bei Walter Benjamin (German Edition) Heiner Weidmann
Die Geburt des Realismus aus dem Dunst des Familienblattes: Fontane und die offentlichkeitsgeschichtlichen Rahmenbedingungen des poetischen Realismus (German Edition) Rudolf Helmstetter
Der Demiurg ist ein Zwitter: Alfred Kubin und die deutschsprachige Phantastik (German Edition)
Dig Up My Heart: Selected Poems 1952-83 Milton Acorn
Die Tragodie Georg Buchners (German Edition) Frida Pongs-Andersson
Die theuren Dinge: Studien zu Bunyan, Jung-Stilling und Novalis (German Edition) Ulrich Stadler
Blick und Bild im Spannungsfeld von Sehen, Metaphern und Verstehen (Schriften der Academie du Midi) (German Edition)
Hermann Hesse Aquarelle 2004. Kunstkarten-Einsteck-Kalender. Edward Tenner
Die deutschen Volkstanze in Bohmen, Mahren und Schlesien (Schriftenreihe der Kommission fur Ostdeutsche Volkskunde in der Deutschen Gesellschaft fur Volkskunde) (German Edition) Helga Thiel
Deutschland und Frankreich im neuen Europa: Referate, Berichte, Dokumente (Arbeitspapiere zur internationalen Politik) (German Edition)
Der Dichter als Kommandant: D'Annunzio erobert Fiume (German Edition)
Das grosse Buch der Dritten Welt: Schlussel zum Verstehen d. Weltprobleme (German Edition) Richard Friedrich
Fur Dich: Collage d'amour (German Edition)